Navigation Links
Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
Date:5/20/2008

- Data from two clinical trials presented at International ATS Conference -

NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist(TM) Inhalation Solution (formoterol fumarate inhalation solution; FFIS) has a pharmacodynamic and pharmacokinetic profile that is comparable to the dry powder inhaler (DPI) formulation of formoterol fumarate, Foradil(R) Aerolizer(R) 12mcg (FA).

Perforomist(TM) (formoterol fumarate) Inhalation Solution, the only FDA- approved nebulized formoterol fumarate, was approved in 2007 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

The first of the two studies presented, "Dose-Ranging Study in COPD Patients Comparing Pharmacodynamics of Formoterol Fumarate Delivered by Nebulization and DPI," showed that 20mcg of FFIS (Perforomist(TM) Inhalation Solution) delivered by nebulization provides bronchodilation comparable to DPI delivery.

The second study; "A Pharmacokinetic Study in COPD Patients Comparing Formoterol Fumarate Delivered by Nebulization and DPI," showed comparability in linear kinetics and excreted drug levels between formoterol fumarate administered by nebulization and DPI. Transient and dose-related effects on serum potassium, serum glucose and vital signs were observed and found to be comparable between the two formulations.

Dr. Nicholas J. Gross, MD, PhD, Hines VA Hospital, Stricht Loyola School of Medicine and lead clinical investigator in the first study, commented, "The results of both of these studies provide additional evidence of the clinical benefit of Perforomist(TM) Inhalation Solution as a valuable treatment option for patients with COPD. Nebulization is an alternative way to deliver medication to the lungs and since many patients may have diffic
'/>"/>

SOURCE Dey L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
2. New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
3. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
4. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
5. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
6. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
7. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
8. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
9. Clarient to Commercialize Novel Breast Cancer Profile
10. Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400
11. Derma Sciences MEDIHONEY(TM) Profiled in Several Television News Health Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... of Spinal Muscular Atrophy SOUTH PLAINFIELD, N.J. and NEW ... the Spinal Muscular Atrophy (SMA) Foundation today announced the ... Foundation will provide up to $8.5 million in funding ... the collaboration to fund a series of research projects ...
... 12 NovImmune, an,immunology-focused biotech company dedicated to ... it has raised CHF,62.5 million (USD 54.8 million) ... and NI-0501, a fully human monoclonal antibody to ... its pipeline.,The transaction was led by BZ Bank ...
... (Nasdaq: VRUS ), a clinical stage pharmaceutical ... to treat viral infections, reported financial results and operational ... Financial Results Revenues were $1.9 million during the ... for the quarter ended March 31, 2008 and reflect ...
Cached Biology Technology:PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8
(Date:7/31/2014)... cells, are inherently different. Each of these cell types ... in metabolism. In the human body, white adipose tissue ... is energy storage. On the other hand, brown adipocytes ... found in a few places in the adult human ... brown adipocytes, appear mixed with brown adipocytes in human ...
(Date:7/31/2014)... shown that marine noise can affect animal movement and ... of Bristol and Exeter and the cole Pratique des ... boat noise stops embryonic development and increases larval mortality ... slug Stylocheilus striatus used in this study) ... later feed on toxic alga but this study, conducted ...
(Date:7/30/2014)... regulate its genes, and adapt to changes in its ... regulation taking place in the truffle, is published in ... illustrates how the truffle deals with its complex genome,s ... may shed light on how traits like aroma and ... known as Prigord truffles, have a syrupy sweet flavor ...
Breaking Biology News(10 mins):Hope for the overweight 2Boat noise impacts development and survival of sea hares 2How black truffles deal with the jumpers in their genome 2
... The next generation of biometric technology launches today with ... by University of Toronto engineering graduates. The Nymi is ... unique heartbeat to unlock your identity. The convenient and ... sensor. When the Nymi recognizes your personal ECG, it ...
... American Association of Pharmaceutical Scientists (AAPS) ... gather to share the latest groundbreaking scientific discoveries and ... Exposition. ,The event will bring together more than 8,000 ... discuss current initiatives underway aimed at improving global health ...
... The science and engineering capabilities that underpin the ... nation,s three national security laboratories are "healthy and vibrant," ... The committee that wrote the report found no ... would prevent certification of the stockpile. However, the report ...
Cached Biology News:Nymi by Bionym launches using your unique heartbeat to unlock your world 2New report reviews science and engineering quality at national security laboratories 2
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... total protein western blot (WtPAN) ... tissue specific protein expression in ... protein is included in each ... for comparison between different western ...
Biology Products: